Eric Bjerkholt Sells 1,421 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 1,421 shares of Mirum Pharmaceuticals stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total value of $132,621.93. Following the transaction, the chief financial officer owned 42,127 shares in the company, valued at $3,931,712.91. This trade represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $94.29 on Friday. The business has a 50-day simple moving average of $77.33 and a two-hundred day simple moving average of $70.78. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $96.84. The stock has a market cap of $4.85 billion, a price-to-earnings ratio of -109.64 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The company had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm’s revenue was up 47.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.30) EPS. On average, analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
• Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
• Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
• Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
• Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert

Wall Street Analyst Weigh In

MIRM has been the topic of a number of analyst reports. Evercore ISI restated an “outperform” rating and set a $101.00 target price on shares of Mirum Pharmaceuticals in a research note on Tuesday. Raymond James Financial reissued a “strong-buy” rating and set a $110.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. JMP Securities set a $95.00 price objective on Mirum Pharmaceuticals in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday. Finally, Leerink Partners set a $100.00 target price on Mirum Pharmaceuticals in a research note on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $102.58.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Eventide Asset Management LLC lifted its position in shares of Mirum Pharmaceuticals by 4.4% in the second quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock worth $134,224,000 after buying an additional 110,485 shares in the last quarter. Geode Capital Management LLC grew its holdings in Mirum Pharmaceuticals by 6.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,029,616 shares of the company’s stock valued at $52,405,000 after buying an additional 65,951 shares in the last quarter. Wellington Management Group LLP increased its stake in Mirum Pharmaceuticals by 566.8% in the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after acquiring an additional 672,118 shares during the last quarter. Boone Capital Management LLC raised its holdings in shares of Mirum Pharmaceuticals by 6.3% during the 2nd quarter. Boone Capital Management LLC now owns 641,448 shares of the company’s stock worth $32,643,000 after acquiring an additional 38,130 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Mirum Pharmaceuticals by 709.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after acquiring an additional 536,674 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.